Background: Coronary artery disease is an important cause of death in adults and stent insertion is one of the treatment modalities. The most severe adverse effect of a stent insertion is the formation of a thrombus; therefore, antiplatelet agents are used. The addition of cilostazol to lowdose aspirin and clopidogrel results in a better antiplatelet effect. However, laboratory tests to monitor the effect of cilostazol are insufficient. Methods: We tested the inhibitory effect of cilostazol using maximal platelet aggregation in 20 healthy volunteers. Conditions for incubation and concentrations of cilostazol and prostaglandin E1 (PGE1) were established and aggregation was induced by 5´-adenosine diphosphate (ADP) and measured with light transmission aggregometry (LTA). Blood samples were incubated with 1 μM and 2 μM cilostazol for 10 minutes at room temperature, and 80 nM PGE1 was added and incubated for an additional 10 minutes. Aggregation was induced by ADP and reactivity was evaluated. Results: The average maximum aggregation (MA) was 58.1% at 1 μM cilostazol and 22.0% when PGE1 was added. The average MA was 42.8% when cilostazol concentration was increased to 2 μM and 21.2% when PGE1 was added. Average inhibition of aggregation at 1 μM cilostazol was not statistically significant (P =0.085), but was significant (P =0.004) at 2 μM cilostazol. Aggregation was not inhibited even with 2 μM cilostazol and PGE1 in 2 volunteers, which suggests possible resistance to cilostazol. Conclusions: We designed a method to monitor the effect of cilostazol using in vitro incubation with PGE1.
INTRODUCTION
Among patients with stent insertions, the addition of cilostazol, which acts differently from aspirin and clopidogrel, resulted in a better prognosis than a dual therapy [4] . Cilostazol increases the level of cAMP by inhibiting phosphodiesterase 3 (PDE3), which degrades cAMP. Increased cAMP phosphorylates vasodilator-stimulated phosphoprotein (VASP) and inhibits platelet aggregation.
Many efforts, such as measuring phosphorylated VASP and directly measuring cAMP, have been made to monitor the pharmacological effect of cilostazol [5] . However, resistance to cilostazol has not been reported since the methods for monitoring the effect of cilostazol are not widely used.
It is reported that the addition of prostaglandin E1 (PGE1) signi cantly increases the phosphorylation of VASP resulting in decreased platelet aggregation compared to cilostazol alone [6] . PGE1 stimulates adenylate cyclase (AC) and increases the level of cAMP, strengthening its antiplatelet effect. We report the development of a method to monitor the effect of cilostazol using in vitro incubation of PGE1 and cilostazol.
METHODS

Subjects
Twenty healthy volunteers without any family history of bleeding disorders agreed to participate in the experiment. Blood was withdrawn in 3.2% sodium citrate tubes and all tests were carried out within 4 hours.
Reagents
1) Cilostazol
A stock solution of 1 mM cilostazol (Sigma Aldrich, MO, USA) was prepared using dimethyl sulfoxide (DMSO, Sigma Aldrich, MO, USA). The stock solution of cilostazol (C20H27N5O2) was diluted to yield nal concentrations of 1 µM, 2 µM, 5 µM, and 10 µM.
2) PGE1
Aliquots were made from 1 mg of PGE1 dissolved in distilled water. PGE1 (1 mM) was additionally diluted to yield nal concentrations of 10 nM, 40 nM, 70 nM, 80 nM, and 100 nM.
3) ADP
ADP (Helena Laboratories, TX, USA) was dissolved in distilled water to produce aliquots. ADP (C10H15N5O10P2; 0.2 mM), in powdered form, was dissolved in 1 mL of distilled water to yield anal concentration of 20 µM.
Platelet Aggregometry
Platelet aggregometry was carried out with PACKS-4, a Platelet Aggregation Chromogenic Kinetic System (Helena Laboratories, TX, USA). The number of platelets was measured. The samples were centrifuged at 800 RPM (140 g) for 600 seconds and supernatants were collected as platelet rich plasma (PRP). The remaining samples were additionally centrifuged at 3,000 RPM (2,090 g) for 900 seconds and the supernatants were collected as plateletpoor plasma (PPP). If necessary, the nal number of platelets in For PGE1, various concentrations of cilostazol were added to 10 nM, 40 nM, 80 nM, and 100 nM PGE1 and the MA was measured.
Establishing Concentrations
Methods
The appropriate concentrations of ADP, PGE1, and cilostazol to be used in screening tests were established as previously explained 
RESULTS
Concentration of ADP
The average MA of samples induced with 20 µM ADP was 77.3% whereas that of the samples incubated with 2 µM cilostazol and 80 nM PGE1 was 18.6%. The average MA of samples induced with 5 µM ADP was 62.0% whereas that of the samples incubated with 2 µM cilostazol and 80 nM PGE1 was 5.6%, which provided a near baseline graph. We decided to use 20 µM ADP in our experiments.
Concentration of Cilostazol
When 10 µM cilostazol was added, the MA was 1.8% even in the absence of PGE1. The MA of samples containing 80 nM PGE1 and 1, 2, and 5 µM cilostazol were 13.1%, 4.8%, and 4.6%, respectively. Aggregation was inhibited signi cantly at 2 µM cilostazol.
The response to 1 µM cilostazol was expected to show individual variations. We decided to use 1 µM and 2 µM cilostazol in our experiments.
Concentration of PGE1
The average MA of samples induced by 20 µM ADP and 2 µM cilostazol, and with the addition of 10 nM, 40 nM, 70 nM, and 100 nM PGE1 was 35.2%, 24.4%, 14.3%, and 8.6%, respectively, and the rate varied among individuals. Aggregation decreased almost proportional to the concentration of PGE1 when more than 40 nM was added. We decided to use 80 nM PGE1 in our experiments. When two samples, one with 100 nM PGE1 and the other with none, were induced by 20 µM ADP, the MA showed no signi cant difference (Fig. 2) . Addition of PGE1 to cilostazol showed a marked effect on the inhibition of platelet aggregation (Fig. 3 ).
Frequency of Resistance to Cilostazol in Normal Population
The 20 volunteers who participated in this experiment compris ed when 80 nM PGE1 was added to 2 µM cilostazol (P <0.001) (Fig. 4) .
Two subjects (both women, aged 29 and 55 yr, with platelet counts of 178×10 3 /µL, 150×10 3 /µL, respectively) showed an MA of over 70% even with PGE1 and 2 µM cilostazol (Fig. 5) . This decreased to nearly 30% when the amount of cilostazol was increas ed to 10 µM and less than 5% when PGE1 was added.
At 2 µM cilostazol and 80 nM PGE1, which is the theoretical condition for the maximum inhibition of aggregation in our experiment, MA was maximum 74.1%, minimum 2.3%, average 21.2%
and standard deviation was 22.2% (Fig. 6 ). In conclusion, we propose incubation with 2 µM cilostazol and 80 nM PGE1 and induction with 20 µM ADP to monitor cilostazol resistance, and the cutoff for resistance to be 65.6% which is the average+2SD.
DISCUSSION
Monitoring the effect of cilostazol, which is prescribed together with aspirin and clopidogrel, is important. Although the response to cilostazol is expected to differ among individuals, there is no report on any methods of monitoring. We developed an experiment protocol using 1 µM and 2 µM cilostazol, and PGE1, to monitor the inhibition of platelet aggregation.
In a study by Yamamoto et al. [6] , 10 healthy volunteers took 100 mg of cilostazol and had blood withdrawn hourly for several hours; thereafter, the level of VASP phosphorylation was measured by western blot analysis. PGE1 was added to the samples and LTA was measured after inducing aggregation with ADP and collagen, indicating that PGE1 is important in monitoring the ef- increases cAMP by acting on Gαs-coupled receptors. It has been proven that cAMP induces nitric oxide synthase in endothelial cells and increases cGMP levels [7] . It is anticipated that the effect of cilostazol was absent without PGE1 since the half-lives of prostacyclin and nitric oxide are 6-7 minutes and a few seconds, respectively. The substances are regarded to be degraded within 20 minutes of preparing PRP.
In 2 volunteers, the activity of platelets was not inhibited even in the presence of 2 µM cilostazol and PGE1, and showed a response when cilostazol concentration was increased to 10 µM. This is expected to be the reaction in patients demonstrating resistance to cilostazol. Theoretically, increasing the dosage of cilostazol, elongating the time of exposure with platelets, or administration of PGE1, can be considered in patients with HPPR to cilostazol. One report showed that an increase in the incubation time of cilostazol had no effect on aggregation when induced by collagen but a signi cant decrease of aggregation was observed when it was induced by ADP [1] . It is thought that increasing the time of exposure to cilostazol increases the amount of cAMP, and compensates for the process where ADP blocks the production of cAMP via the P2Y12 receptor. Although the time of exposure of platelets to cilostazol will vary among individuals according to their metabolism rate, we carried out our experiment based on the hypothesis that an incubation of 10 minutes was enough.
Aggregation of platelets was observed to be signi cantly inhibited at 1 µM and 2 µM cilostazol, among various concentrations of cilostazol, and concentrations of 1 µM and 2 µM were used in experiments with volunteers. According to the literature, the peak level of cilostazol is achieved at 2-4 hr after the administration of 100 mg of cilostazol and its concentration is 2 µM [8] , showing a similarity with the 1 µM and 2 µM concentrations used in our experiment.
Methods for monitoring the effects of aspirin and clopidogrel are developed and considerable research has been performed on the mechanisms of resistance of these two medications. When aspirin is taken with ibuprofen, the two forms of medication competitively interact with COX-1 receptors leading to a decreased effect [9] . Increased active oxidants may lessen the antiplatelet effect in hyperglycemic patients [10] and aspirin may have a decreased effect on thrombin in patients with high cholesterol levels [11] . In addition, increased secretion of catecholamine due to exercise and stress is suggested as a reason for the inhibited effects of aspirin [12] .
Cilostazol is presently used for peripheral artery diseases especially in Asian countries such as Korea and Japan [13] . It not only inhibits PDE3 but also decreases platelets that are activated by interaction with stimulated endothelial cells and prevents restenosis of vessels by blocking the proliferation of smooth muscles of vessel walls [13] . About 4% of patients who took clopidogrel showed abnormal liver function within 52 weeks [14] . Antacids are recommended with clopidogrel and low-dose aspirin because gastric bleeding may occur [15, 16] . About 38% of patients taking lowdose aspirin develop ulcer and mucocutaneous erosion upon endoscopic examination whereas less than 20% of patients with clopidogrel and cilostazol showed such endoscopic ndings [17] .
In one study, 60 patients with HPPR to clopidogrel were divided into two groups, one with addition of cilostazol and the other with increased dose of clopidogrel. The group with the addition of cilostazol showed a signi cantly decreased platelet aggregation rate [18] . The use of cilostazol will increase due to its advantages and emerging problems of other antiplatelet agents, and as such, monitoring of its effects will be necessary.
We developed a convenient in vitro incubation method of monitoring the effect of cilostazol without having patients take cilostazol. Further research on whether the results re ect an accurate in vivo effect is necessary. Furthermore, the cilostazol used in our experiment was the pure form of cilostazol whereas patients take 
